BMYB34:BVMF
Bristol-Myers Squibb Company BDR
331,90 R$
arrow_upward
+0,65%(+2,15) 1 d.
30. sept., 11:31:25 GMT-3 · BRL
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: BMYB34…
Tirgus kapitalizācija
125,89 mljrd.
Vid. apjoms
10,00
Apjoms
0,00
Augstākā 52 ned.
347,15 R$
Zemākā 52 ned.
221,72 R$
Apgrozībā esošās akcijas
2,04 mljrd.
Darbinieku skaits
32 tūkst.
Tirgus kapitalizācija
125,89 mljrd.
Vid. apjoms
10,00
Apjoms
0,00
Augstākā 52 ned.
347,15 R$
Zemākā 52 ned.
221,72 R$
Apgrozībā esošās akcijas
2,04 mljrd.
Darbinieku skaits
32 tūkst.
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
AD HOC NEWS
·
pirms 5 stundām
Leerink cuts target for Bristol Myers Squibb stock to USD 59.00
The Globe and Mail
·
pirms 8 stundām
Zacks.com featured highlights Dollar General, Bristol-Myers Squibb and Equinor ASA
GuruFocus
·
pirms 11 stundām
Bristol-Myers Squibb Co (BMY) Shares Fall 3.8% -- GF Value Says Still Overvalued
Insider Monkey
·
pirms 17 stundām
Bristol Myers (BMY) Stock is Trading Below 10 Times Forward Earnings. Here’s Why it Matters
Profils
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2025, 69% of the company's revenues came from the United States.
The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000. Wikipedia
Par “Bristol-Myers Squibb Company BDR”
ĢenerāldirektorsChris Boerner
Darbinieki32,5 tūkst.
Dibināšanas datums1887
Galvenais birojsŅujorka, Ņujorka, Amerikas Savienotās Valstis
Sektors-
Tīmekļa vietnebms.com